Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BioLife Solutions Inc is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS) are listed on the NASDAQ and all prices are listed in US Dollars. BioLife Solutions employs 432 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $14.64 |
|---|---|
| 52-week range | $10.40 - $60.67 |
| 50-day moving average | $13.34 |
| 200-day moving average | $29.02 |
| Wall St. target price | $37.13 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.34 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.64 from 2022-07-01
| 1 week (2022-06-28) | -0.14% |
|---|---|
| 1 month (2022-06-03) | 6.40% |
| 3 months (2022-04-05) | -35.79% |
| 6 months (2022-01-05) | -55.35% |
| 1 year (2021-07-02) | -67.62% |
|---|---|
| 2 years (2020-07-02) | -18.58% |
| 3 years (2019-07-05) | 15.71 |
| 5 years (2017-07-05) | 404.83% |
Valuing BioLife Solutions stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLife Solutions's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLife Solutions's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 65.3833. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLife Solutions's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $138.5 million |
|---|---|
| Gross profit TTM | $38.1 million |
| Return on assets TTM | -6.19% |
| Return on equity TTM | -3.95% |
| Profit margin | -9.81% |
| Book value | $11.30 |
| Market capitalisation | $620.9 million |
TTM: trailing 12 months
We're not expecting BioLife Solutions to pay a dividend over the next 12 months.
BioLife Solutions's shares were split on a 1:14 basis on 28 January 2014. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLife Solutions shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for BioLife Solutions shares which in turn could have impacted BioLife Solutions's share price.
Over the last 12 months, BioLife Solutions's shares have ranged in value from as little as $10.4 up to $60.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLife Solutions's is 1.9914. This would suggest that BioLife Solutions's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.